Kyverna Therapeutics, Inc. KYTX
5.22 USD +0.14 (+2.76%)
Nov 11, 2026, 12:34 PM EST
5.02 Day range 5.23
4.50 52-week range 13.67
- YTD
- -44.47%
- 1 year
- -25.43%
Analyst view
Consensus: buy
Buy
Price target (mean) 27.33 +423.6% upside
Now 5.22
- Target (low)
- 6.00
- Target (mean)
- 27.33
- Target (high)
- 48.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy2
- Buy3
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.78512 | -0.87 – -0.63561 | -75.82 | +99.0% | 0 | 0.0% | 5 |
| Next quarter | -0.89333 | -0.99 – -0.72 | -1.12 | +20.2% | 0 | 0.0% | 3 |
| Current year | -3.23 | -3.33 – -3.06 | -89.61 | +96.4% | 0 | 0.0% | 5 |
| Next year | -3.63 | -4.35 – -2.99 | -3.23 | -12.3% | 0 | 0.0% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| Nov 15, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| Oct 10, 2024 | UBS | Initiated | — | Buy |
| Sep 19, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Aug 15, 2024 | HC Wainwright & Co. | Maintained | Neutral | Neutral |
| Jul 31, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Jul 16, 2024 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Jul 3, 2024 | HC Wainwright & Co. | Initiated | — | Neutral |
| Mar 4, 2024 | JP Morgan | Initiated | — | Overweight |
| Mar 4, 2024 | Morgan Stanley | Initiated | — | Overweight |